TORONTO--(BUSINESS WIRE)--May. 29, 2009-- Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced that the Company will participate at the UBS Global Specialty Pharmaceuticals Conference in London, UK and the Goldman Sachs Annual Healthcare Conference in New York, NY.
Biovail’s UBS conference presentation is scheduled for Tuesday, June 2, 2009 at 1:30 PM GMT (8:30 AM EDT). The Goldman Sachs conference presentation is scheduled for Thursday, June 11, 2009 at 11:00 AM EDT. A live and archived Webcast will be available on the Investor Relations page of Biovail’s Web site at www.biovail.com.
About Biovail Corporation
Biovail Corporation is a specialty pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products. The Company is focused on the development and commercialization of medicines that address unmet medical needs in niche specialty central nervous system (CNS) markets. For more information about Biovail, visit the Company’s Web site at www.biovail.com.
For further information, please contact Nelson F. Isabel at 905-286-3000 or send inquiries to [email protected].
Source: Biovail Corporation
Biovail Corporation
Nelson F. Isabel, (905) 286-3000
Vice President, Investor Relations & Corporate Communications
